Having a great expertise in biopharma filtration technology, 3M on May 31, 2023, said it will invest $146 million to increase its capacity to serve biotech production, a rapidly expanding sector of the medical industry that is offering ground-breaking treatments to patients.
Improvements to the buildings and equipment as well as the creation of 60 new full-time jobs at 3M production plants in Europe are part of the investment.
With the help of the new investment, 3M is expected to produce and deliver crucial filtration equipment faster for bioprocessing, biological, and small molecule pharmaceutical manufacturing applications. This will allow its biotech clients to keep developing cutting-edge therapies for diseases like rheumatoid arthritis, multiple sclerosis, and specific cancers. When creating biopharmaceutical medications, filtration, and purification are crucial steps. The method makes use of a special filter material that traps contaminants while letting the essential medicinal ingredients flow through.
President of 3M Separation and Purification Sciences Division, Robert Befidi said “Our investment further demonstrates 3M’s continued market leadership and ongoing commitment to customer-centric innovation in health care”. Furthermore, he said, “Our technologies improve the lives of people all over the world, and we are helping biotech customers do more, faster, to advance their specialized medicines.”
In the biopharmaceutical sector, 3M has the broadest selection of depth filters for cell culture clarity. Globally, the clearing of medicinal goods containing cell-derived proteins is greatly aided by the use of the Zeta Plus depth filtering technology in cartridge systems and sheets.
Must View: LG Chem to Provide $200 Million Worth Essential Vaccinations to UNICEF
